10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

LITAF Blocking Peptide (N-Term)

Synthetic peptide
Catalog # BP21944a

Specification

LITAF Blocking Peptide (N-Term) - Product Information

Primary Accession	Q99732
Other Accession	Q9JLJ0, P0C0T0

LITAF Blocking Peptide (N-Term) - Additional Information

Gene ID 9516

Other Names
Lipopolysaccharide-induced tumor necrosis factor-alpha factor, LPS-induced TNF-alpha factor, Small integral membrane protein of lysosome/late endosome, p53-induced gene 7 protein, LITAF, PIG7, SIMPLE

Target/Specificity
The synthetic peptide sequence is selected from aa 51-60 of HUMAN LITAF

Format
Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage
Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions
This product is for research use only. Not for use in diagnostic or therapeutic procedures.

LITAF Blocking Peptide (N-Term) - Protein Information

Name LITAF

Function
Plays a role in endosomal protein trafficking and in targeting proteins for lysosomal degradation (PubMed:23166352). Plays a role in targeting endocytosed EGFR and ERGG3 for lysosomal degradation, and thereby helps down-regulate downstream signaling cascades (PubMed:23166352). Helps recruit the ESCRT complex components TSG101, HGS and STAM to cytoplasmic membranes (PubMed:23166352). Probably plays a role in regulating protein degradation via its interaction with NEDD4 (PubMed:15776429). May also contribute to the regulation of gene expression in the nucleus (PubMed:10200294, PubMed:15793005). Binds DNA

(in vitro) and may play a synergistic role with STAT6 in the nucleus in regulating the expression of various cytokines (PubMed:15793005). May regulate the expression of numerous cytokines, such as TNF, CCL2, CCL5, CXCL1, IL1A and IL10 (PubMed:10200294, PubMed:15793005).

Cellular Location
Cytoplasm. Nucleus. Lysosome membrane; Peripheral membrane protein; Cytoplasmic side. Early endosome membrane. Late endosome membrane. Endosome membrane; Peripheral membrane protein; Cytoplasmic side. Cell membrane; Peripheral membrane protein; Cytoplasmic side. Golgi apparatus membrane. Note=Associated with membranes of lysosomes, early and late endosomes (PubMed:11274176, PubMed:27927196, PubMed:27582497). Can translocate from the cytoplasm into the nucleus (PubMed:15793005). Detected at Schmidt-Lanterman incisures and in nodal regions of myelinating Schwann cells (By similarity) {ECO:0000250|UniProtKB:Q9JLJ0, ECO:0000269|PubMed:11274176, ECO:0000269|PubMed:15793005, ECO:0000269|PubMed:27582497, ECO:0000269|PubMed:27927196}

Tissue Location
Ubiquitously and abundantly expressed. Expressed predominantly in the placenta, peripheral blood leukocytes, lymph nodes and spleen.

LITAF Blocking Peptide (N-Term) - Protocols

Provided below are standard protocols that you may find useful for product applications.

- Blocking Peptides

LITAF Blocking Peptide (N-Term) - Images

LITAF Blocking Peptide (N-Term) - Background

Probable role in regulating transcription of specific genes. May regulate through NFKB1 the expression of the CCL2/MCP-1 chemokine. May play a role in tumor necrosis factor alpha (TNF-alpha) gene expression.

LITAF Blocking Peptide (N-Term) - References

Polyak K.,et al.Nature 389:300-306(1997).
Myokai F.,et al.Proc. Natl. Acad. Sci. U.S.A. 96:4518-4523(1999).
Moriwaki Y.,et al.J. Biol. Chem. 276:23065-23076(2001).
Ota T.,et al.Nat. Genet. 36:40-45(2004).
Bechtel S.,et al.BMC Genomics 8:399-399(2007).